-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎ WuXi AppTec content team editor
Today, at the annual meeting of the European Society of Oncology (ESMO), amgen's KRAS G12C inhibitor Lumakras (sotorasib) released
KRAS gene mutations are one of the most common oncogene mutations in cancer patients, and it was once a well-known "incurable" target
CodeBreaK 200 is a randomized, active-controlled, phase 3 clinical trial designed to compare the efficacy and safety
Trial results showed that in these patients who had received multiple pre-treatments, Lumakas reduced the risk of disease progression or death by 34% compared with standard chemotherapy (HR: 0.
"The overall evidence for this study supports Lumakras as an important targeted therapy option for patients with non-small cell lung cancer carrying KRAS G12C mutations and highlights the urgent need
Krass-targeted drug development has developed rapidly in recent years, and in addition to Amgen's Lumakras, Mirati's Adagrasib is being reviewed by the U.